DelveInsight’s Ulcerative Colitis Market report offers a detailed comprehension of the Ulcerative Colitis market size by treatment, epidemiology, and emerging therapies. The report also provides an understanding of Ulcerative Colitis market share of the individual therapies, current and forecasted Ulcerative Colitis market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Key highlights from the Ulcerative Colitis Market Insight report
- According to an estimate by DelveInsight, the highest Ulcerative Colitis prevalent cases in the 7MM were found in the United States with 1,008,823 which accounted for nearly 46% of the total 7MM cases, in the year 2020.
- Key pharma players working proactively in the Ulcerative Colitis therapeutic market are Gilead Sciences, Galapagos NV, AbbVie, Eli Lilly and Company, Arena Pharmaceuticals, Janssen (Johnson & Johnson), Theravance Biopharma, Landos Biopharma, and several others in the clinical development stage for Ulcerative Colitis will lead to a significant increase in the market size during the forecast period.
- The key therapies expected to launch in the Ulcerative Colitis market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi (Risankizumab), Mirikizumab (LY-3074828), Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11, and others.
- According to DelveInsight analysis, the Ulcerative Colitis market is expected to rise in the coming years due to the entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, increasing prevalence of Ulcerative Colitis, and new biomarkers for diagnosis of Ulcerative Colitis.
- The major reason behind the Ulcerative Colitis market upsurge would be the improvement in the rise in the number of healthcare spending across the world.
For further information on Market Impact by Therapies, Download Ulcerative Colitis Market sample @ Ulcerative Colitis Treatment Landscape
Ulcerative Colitis: Overview
Two major types of Inflammatory Bowel Disease (IBD) are Ulcerative Colitis (UC) and Crohn’s Disease (CD). Ulcerative Colitis is limited to the colon or large intestine. Approximately 10% of cases of IBD exhibit the features of both Ulcerative Colitis and Crohn’s Disease. These are typically known as Indeterminate Colitis (IC).
There are different types of Ulcerative Colitis, categorized by the cause of the disease: Ulcerative proctitis, Proctosigmoiditis, Left-sided colitis (also limited or distal colitis), Pancolitis, and Extensive Colitis. There is no single test to diagnose Ulcerative Colitis, instead, the IBD team takes into consideration the symptoms together with the results of Endoscopies, Biopsies, Blood and Stool tests, X-rays, and Imaging Procedures.
Request for a Webex demo of the report @ Ulcerative Colitis Market Report
Ulcerative Colitis Epidemiology Segmentation
DelveInsight’s analysts indicate that the total diagnosed cases of Ulcerative Colitis in the 7MM were 1,577,979 in 2020. These cases are expected to rise by 2030, during the forecast period.
The Ulcerative Colitis Report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
- Total Prevalent Ulcerative Colitis Cases
- Total Diagnosed Prevalent Ulcerative Colitis Cases
- Age-Specific Diagnosed Prevalent Cases of Ulcerative Colitis
- Severity-Specific Diagnosed Prevalent Cases of Ulcerative Colitis
- Total Treated Ulcerative Colitis Cases
Ulcerative Colitis Pipeline Therapies and Key Companies
- Jyseleca (filgotinib): Gilead Sciences/Galapagos NV
- Rinvoq (Upadacitinib) & Skyrizi(Risankizumab): AbbVie
- Risankizumab (ABBV-066): AbbVie and Boehringer Ingelheim
- Mirikizumab (LY-3074828): Eli Lilly and Company
- Etrasimod: Arena Pharmaceuticals
- Tremfya (Guselkumab): Janssen (Johnson & Johnson)
- Izencitinib (TD-1473/ JNJ 8398): Theravance Biopharma/Johnson & Johnson
- BT-11: Landos Biopharma
Ulcerative Colitis Market Dynamics
The current therapeutic landscape of Ulcerative Colitis in the 7MM is driven by several approved therapies. Also, the Ulcerative Colitis market is expected to surge due to factors such as the increasing prevalence of Ulcerative Colitis, entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, new biomarkers for diagnosis of Ulcerative Colitis and also the involvement of digital technology for diagnosis and treatment.
A high number of undiagnosed and unreported cases contribute to the lack of awareness of Ulcerative Colitis. The entry of biosimilars in the Ulcerative Colitis Market, insufficient knowledge of the disease, and significant drawbacks of existing therapeutic options may act as certain obstructions in the Ulcerative Colitis market.
Scope of the Ulcerative Colitis Report
- Study Period: 2018-30
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Companies: Takeda Pharmaceutical, Pfizer, Celgene (Bristol-Myers Squibb), Gilead Sciences, Galapagos NV, AbbVie, Eli Lilly and Company, Arena Pharmaceuticals, Janssen (Johnson & Johnson), Theravance Biopharma, Landos Biopharma
- Key Ulcerative Colitis Pipeline Therapies: Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi(Risankizumab), Mirikizumab (LY-3074828), Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11
- Therapeutic Assessment: Ulcerative Colitis current marketed and emerging therapies
- Market Dynamics: Ulcerative Colitis market drivers and barriers
- Competitive Intelligence Analysis: Porter’s five forces, SWOT analysis, PESTLE analysis, Market entry strategies, BCG Matrix, Unmet Needs
- KOL views
- Reimbursement Scenario
Table of Contents
|
1 |
Key Insights |
|
2 |
Report Introduction of Ulcerative Colitis |
|
3 |
Ulcerative Colitis Market Overview at a Glance |
|
4 |
Executive Summary of Ulcerative Colitis |
|
5 |
Ulcerative Colitis Epidemiology and Market Forecast Flow |
|
6 |
Ulcerative Colitis: Disease Background and Overview |
|
7 |
Ulcerative Colitis Diagnosis |
|
8 |
Ulcerative Colitis Current Treatment |
|
9 |
Ulcerative Colitis Epidemiology and Patient Population |
|
10 |
Ulcerative Colitis Patient Journey |
|
11 |
Key Endpoints in Ulcerative Colitis Clinical Trials |
|
12 |
Ulcerative Colitis Marketed Therapies of Ulcerative Colitis |
|
13 |
Ulcerative Colitis Emerging Therapies |
|
14 |
Conjoint Analysis of Ulcerative Colitis |
|
15 |
Ulcerative Colitis: Seven Major Market Analysis |
|
16 |
The United States Market Size |
|
17 |
Ulcerative Colitis Market Access and Reimbursement |
|
18 |
Ulcerative Colitis Market Drivers |
|
19 |
Ulcerative Colitis Market Barriers |
|
20 |
Ulcerative Colitis SWOT Analysis |
|
21 |
Ulcerative Colitis Unmet Needs |
|
22 |
Appendix |
|
23 |
DelveInsight Capabilities |
|
24 |
Disclaimer |
|
25 |
About DelveInsight |
About DelveInsight
DelveInsight is a pioneer in stipulating state-of-the-art services to the clients, also serving as a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market